Zolav®: a new antibiotic for the treatment of acne by Dinant, A & Boulos, Ramiz A
© 2016 Dinant and Boulos. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Drug Design, Development and Therapy 2016:10 1235–1242
Drug Design, Development and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1235
O r i g i n a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/DDDT.S106462
Zolav®: a new antibiotic for the treatment of acne
alexa Dinant1
ramiz a Boulos2,3
1aXD Pty ltd, semaphore Park, 
2school of chemical and Physical 
sciences, Flinders University, 
Bedford Park, 3Boulos & cooper 
Pharmaceuticals Pty ltd, Port 
adelaide, sa, australia
Background: Acne is a prominent skin condition affecting 80% of teenagers and young 
adults and ~650 million people globally. Isotretinoin, a vitamin A derivative, is currently the 
standard of care for treatment. However, it has a well-established teratogenic activity, a reason 
for the development of novel and low-risk treatment options for acne.
Objective: To investigate the effectiveness of Zolav®, a novel antibiotic as a treatment for 
acne vulgaris.
Materials and methods: Minimum inhibitory concentration of Zolav® against Propionibac-
terium acnes was determined by following a standard protocol using Mueller-Hinton broth and 
serial dilutions in a 96-well plate. Cytotoxicity effects on human umbilical vein endothelial 
cells and lung cells in the presence of Zolav® were investigated by determining the growth 
inhibition (GI
50
) concentration, total growth inhibition concentration, and the lethal concentra-
tion of 50% (LC
50
). The tryptophan auxotrophic mutant of Escherichia coli strain, WP2 uvrA 
(ATCC 49979), was used for the AMES assay with the addition of Zolav® tested for its ability 
to reverse the mutation and induce bacterial growth. The in vivo effectiveness of Zolav® was 
tested in a P. acnes mouse intradermal model where the skin at the infection site was removed, 
homogenized, and subjected to colony-forming unit (CFU) counts.
Results: Susceptibility testing of Zolav® against P. acnes showed a minimum inhibitory con-
centration of 2 µg/mL against three strains with no cytotoxicity and no mutagenicity observed 
at the highest concentrations tested, 30 µM and 1,500 µg/plate, respectively. The use of Zolav® 
at a concentration of 50 µg/mL (q8h) elicited a two-log difference in CFU/g between the treat-
ment group and the control.
Conclusion: This study demonstrates the potential of Zolav® as a novel treatment for acne 
vulgaris.
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Introduction
Acne is a prominent skin condition manifesting itself mostly in adolescents. It 
affects ~80% of teenagers and young adults and ~650 million people globally,1 making 
it one of the top ten most common diseases worldwide. It is caused by the bacterium 
Propionibacterium acnes that resides within the pilosebaceous follicles, adjacent to 
the sebaceous glands. Although it is still unknown what triggers it, the overproduc-
tion of sebum by these glands, or the blockage of follicles, causes the overgrowth 
of P. acnes, which causes inflammation in the skin.2 It is often accompanied with 
a feeling of discomfort and affects the physical appearance and self-esteem of affected 
individuals.2
Current treatment options for acne include the use of topical and oral treatments, 
including hormonal agents.3 Benzoyl peroxide is a bactericidal topical agent used 
for the treatment of mild to moderate acne, but it is ineffective in severe acne.3 
Topical antibiotics such as erythromycin and clindamycin are used in more serious 
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acne cases; however, the decreased sensitivity of P. acnes 
to these antibiotics has limited their use as monotherapies.3 
Oral antibiotics have also been used; however, resistance 
emergence aside,4,5 adverse effects such as photosensitivity 
associated with the use of doxycycline and skin and teeth 
pigmentation associated with the use of minocycline have 
been reported.3 The standard of care for the treatment of 
acne is the use of isotretinoin, a vitamin A derivative, and 
although effective, isotretinoin has a number of adverse 
effects affecting the mucocutaneous, musculoskeletal, 
and ophthalmic systems as well as the central nervous 
system.3 Side effects can include changes in mood, suicide 
ideation, and headaches.3 However, the biggest side effect 
of isotretinoin comes from its teratogenic effect on the fetus 
during pregnancy,2,3 and it is therefore a legal requirement 
to consent to effect nonpregnancy during treatment and at 
least 4 weeks after treatment. Often, a number of treatment 
options are combined4 to deliver the best outcome, although 
this comes at the expense of the treatment cost. In light of 
the above discussion, there is a need for new and low-risk 
treatment options for acne vulgaris.
We have recently reported the in silico modeling that 
led to the discovery of a new class of antibiotics that target 
the novel mechanosensitive ion channel of large conduc-
tance (MscL).6 MscL channels have evolved the ability to 
translate the mechanical stress across the membrane into an 
electrochemical response by opening up and allowing the 
loss of solutes and small proteins from within the bacteria, 
thereby preventing cell lysis.7 MscL channels are highly 
conserved in bacterial species and absent in the human 
genome and are hence a highly sought after target for drug 
discovery. We have found that by interacting with these 
channels, this new class of antibiotics can inhibit the growth 
of bacteria.6 This new class has a number of competitive 
advantages, including a highly efficient and economical 
chemical synthesis,8,9 antioxidant properties,7 and, with 
relevance to a topical therapeutic agent for acne treatment, 
high chemical stability. Here, we present the effectiveness 
of Zolav®, a first-generation antibiotic belonging to that class 
in the treatment of acne, noting that resistance emergence of 
another antibiotic in the same class is very low.10 We present 
the in vitro efficacy of Zolav® against a number of P. acnes 
strains, and we show that Zolav® has low cytotoxicity against 
human umbilical vein endothelial cells (HUVEC) and lung 
cells and no mutagenic activity at therapeutic concentration. 
Finally, we present the effectiveness of topically adminis-




Zolav® was provided by Boulos & Cooper Pharmaceuticals 
Pty Ltd (Port Adelaide, SA, Australia) and stored until 
needed. Aroclor 1254-induced male Sprague Dawley rat 
liver S9 was purchased from Molecular Toxicology, Inc. 
(Boone, NC, USA) (Cat# 11-01L.2). β-nicotinamide adenine 
dinucleotide phosphate, 2-Aminoanthracene and tryptophan 
were purchased from Sigma-Aldrich Co. (St Louis, MO, 
USA). Glucose-6-phosphate, glucose, dimethyl sulfoxide 
(DMSO) and potassium dichromate were purchased from 
Merck Millipore (Billerica, MA, USA), and magnesium 
chloride, potassium phosphate dibasic, potassium chlo-
ride, sodium dihydrogen phosphate and sodium chloride were 
purchased from Wako Pure Chemical Industries, Ltd (Osaka, 
Japan). Bacto agar (DIFCO, Carolina Biological Supply 
Company, Burlington, NC, USA), bottom agar (containing 
1.5% bacto agar, 2% glucose, and 2% Vogel-Bonner salt), 
nutrient broth (Oxoid Ltd, Hampshire, England), and top 
agar (0.6% bacto agar and 0.5% NaCl supplemented with 
0.025 mM tryptophan) were stored according to the manu-
facturer’s instructions until needed.
Bacterial cultures
Escherichia coli, WP2 uvrA (ATCC 49979), P. acnes ATCC 
6919, ATCC 29399, and ATCC 11827 were obtained from the 
American Type Culture Collection (Manassas, VA, USA).
Minimum inhibitory concentration testing
The antimicrobial potency of Zolav® was measured using 
the in vitro broth microdilution assay under assay conditions 
described by the Clinical and Laboratory Standards Institute. 
In this assay, the minimum inhibitory concentration (MIC) 
is defined as the lowest concentration of an agent that com-
pletely inhibits visible growth in vitro of the microorganism. 
The test substance was dissolved in 100% DMSO, suspended 
completely by sonication or vortexing, and diluted by twofold 
serial titrations in the same vehicle, for a total of eleven test 
concentrations. A 2 µL aliquot of each dilution was added to 
198 µL of broth medium seeded with the organism suspension 
in wells of a 96-well plate (bacterial count: 2–8×105 CFU/mL 
final). The final volume was 200 µL in each well, and the final 
DMSO concentration was 1%. Following incubation, the test 
plates were visually examined and wells were scored for growth 
or complete growth inhibition to define the MIC. Each test 
substance was evaluated in duplicate, and the results presented 
are the duplicate test values. Vehicle control and clindamycin 
were used as blank and positive controls, respectively.
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cytotoxicity testing
HUVEC cells (ATCC CRL-1730), A549 human lung 
carcinoma cells (ATCC CCL-185), and NCI-H460 cells 
human lung carcinoma (ATCC HTB-177) (1.5×104/mL 
in growth medium) were placed in 96-well plates in an 
atmosphere of 5% CO
2
 at 37°C for overnight incubation. 
Zolav® was screened at 30 µM, 3 µM, 0.3 µM, 0.03 µM, 
and 0.003 µM. Staurosporine was used as a control. Zolav® 
and/or vehicle was then added, and the plates were incu-
bated for an additional 72 hours. After 72-hour incubation, 
luminescence was measured using a microplate reader. 
Growth inhibition (GI
50
) (concentration that produces 50% 
growth inhibition), total growth inhibition or cytostatic 
effect, and lethal concentration of 50% (LC
50
) (concentra-
tion that produces 50% growth, a cytotoxicity parameter) 
represent cell growth with 50% reduction of the vehicle-
treated control (T
72
), equal to the cell growth of the begin-
ning cell density (T
0
), and a loss of cells of 50% relative to 
the beginning cell density (T
0
), respectively. The cell lines 
followed ATCC’s regulations and the use of cell lines for 
in vivo studies were monitored under IACUC (Institutional 
Animal Care and Use Committee) and IBC (Institutional 
Biosafety Committee).
aMes test
The tryptophan auxotrophic mutant of E. coli strain, WP2 
uvrA (ATCC 49979), was used. The test strain was obtained 
from the frozen working stock vial and thawed at room 
temperature. A 0.2 mL aliquot was inoculated into 25 mL 
nutrient broth medium and then incubated at 35°C–37°C 
with shaking (120 rpm) for 16–18 hours. Zolav® was dis-
solved in DMSO and diluted, tenfold, to obtain four stock 
concentrations of 15,000 µg/mL, 1,500 µg/mL, 150 µg/mL, 
and 15 µg/mL. Rat liver microsome enzyme homogenate 
(S9) mixture was prepared, containing 8 mM MgCl
2
, 33 mM 
KCl, 4 mM β-nicotinamide adenine dinucleotide phosphate, 




 (pH 7.4), and 
4% (v/v) Aroclor 1254-induced male rat liver microsome 
enzyme homogenate (S9). Stock test compound solution, 
0.1 mL, was combined with strain culture, 0.1 mL, and with 
0.5 mL rat liver enzyme homogenate (S9) mixture or 0.5 mL 
phosphate buffer saline and then incubated at 35°C–37°C 
with shaking (120 rpm) for 20 minutes. Molten top agar 
(2 mL, containing 0.025 mM tryptophan) was added, and the 
mixture was poured on to the surface of a minimal glucose 
agar plate (30 mL bottom agar per petri dish) to obtain final 
test substance concentrations of 1,500 µg/plate, 150 µg/plate, 
15 µg/plate, and 1.5 µg/plate. The plates were incubated at 
37°C for 72 hours, and then the numbers of revertant colonies 
were counted. Treatments resulting in a $ threefold increase 
in revertant colonies relative to vehicle control are consid-
ered mutagenic. Treatments that reduce the colony count to 
50% of vehicle control are considered cytotoxic. Assays 
were performed in triplicate.
animals
Female BALB/c mice, ordered from Harlan Sprague 
Dawley Inc. (Indianapolis, IN, USA) weighing 17–19 g, 
were acclimated to housing conditions for 4 days prior to 
bacterial challenge. Only animals deemed healthy and fully 
immunocompetent were included in this study. Cages were 
prepared with three or five mice per cage. The animals were 
fed Teklad Global Rodent Diet (Harlan) and water ad libi-
tum. Mice were housed in static cages with Teklad 1/8″ corn 
cob bedding inside bioBubble® Clean Rooms that provide 
high-efficiency particulate air (HEPA) filtered air into the 
bubble environment at 100 complete air changes per hour. 
All treatments and infectious challenges were carried out in 
the bioBubble environment. The environment was controlled 
to a temperature of ~25°C and a humidity of 50%. Treatment 
groups were identified by cage card. All procedures carried 
out in this experiment were conducted in compliance with all 
the laws, regulations, and guidelines of the National Institutes 
of Health and with the approval of the TransPharm Animal 
Care and Use Committee.
skin preparation
On Day 1, each mouse was anesthetized in an isoflurane induc-
tion chamber and the lesion site was cleared of hair. An area 
of ~2.0 cm ×2.0 cm of skin on the dorsal area of each mouse 
was cleared through use of the depilatory agent Nair®.
challenge
Cultures were grown for 96 hours at 37°C in an anaerobic 
atmosphere on tryptic soy agar plates supplemented with 
5% sheep blood cells. The culture was aseptically swabbed 
and transferred to tubes of Brain–Heart Infusion broth and 
allowed to grow for 72 hours. The cultures were diluted to 
provide challenge inoculum of ~7.0 log 10 CFU per 50 µL 
in phosphate buffer saline. On Day 0, each mouse was 
anesthetized using isoflurane. Each animal on the study 
was administered 50 µL of the bacterial suspension via 
intradermal injection in the dorsal area that was previously 
denuded of hair. The final CFU count from the challenge 
suspension determined that 5.6 log 10 CFU per mouse 
were delivered.






Zolav® in the aqueous form was provided by Boulos & Cooper 
Pharmaceuticals Pty Ltd. Treatments were administered via 
topical application in a dose volume of 50 µL and spread 
evenly over the infection site. Treatments were administered 
at 2 hours, 10 hours, 18 hours, 26 hours, 34 hours, 42 hours, 
50 hours, 58 hours, 66 hours, 74 hours, 82 hours, and 90 hours 
post-challenge. At the conclusion of the study, mice were 
humanely euthanized and the skin was aseptically removed 
from the infection site. After 2 hours postinfection, mice were 
sacrificed for determining the CFU/g baseline burden. Skin 
samples from mice were placed in homogenation vials with 
2.0 mL tryptic soy broth, weighed, and homogenized using 
a mini-bead beater. The homogenate was serially diluted and 
plated anaerobically on tryptic soy agar plates for enumera-
tion of CFUs per gram of skin tissue.
Results and discussion
MIC testing revealed that Zolav® at a concentration of 
2 µg/mL inhibited the growth of three different strains of 
P. acnes (Table 1). This is a clinically significant result given 
that any successful treatment option for acne must show 
activity against the different strains of P. acnes, in light of 
different strains inducing pathogenicity. For comparison, 
clindamycin has shown an MIC of 0.063 µg/mL against the 
three strains, while gentamycin, ofloxacin, and vancomycin 
have shown MICs of 30 µg/mL, 1 µg/mL, and 1 µg/mL, 
respectively, against P. acnes ATCC 6919.
Acne can affect the back, neck, and the T-zone area of 
affected individuals, and therefore, any topical treatment 
for acne should have low toxicity primarily to the skin and 
secondarily to the lungs, if the drug particles are inhaled. 
HUVEC cells were used here as a model cell line to gauge 
the cytotoxicity of skin cells, with the results showing no 
cell death observed in HUVEC and lung cells at the high-
est concentration tested at 30 µM, at least 7× the MIC of 
Zolav® (Table 2). For comparison, the natural antibiotic 
staurosporine, a promiscuous protein kinase inhibitor, has 
shown cytotoxicity at concentrations significantly lower 
than those of Zolav®.
The tryptophan auxotrophic mutant of the E. coli strain 
(WP2 uvrA, ATCC 49979) is incapable of producing tryp-
tophan due to a mutation in the tryptophan locus. Reverse 
mutations of the strain to tryptophan (Trp+) prototrophy are 
detected as growth on minimal medium that is deficient for 
tryptophan. Induction of reversion (positive mutagenicity) is 
indicated by a threefold increase in the reversion frequency 
of treated groups versus control groups. The results have 
shown that no mutagenic activity was observed at the high-
est concentrations tested of Zolav®, up to 1,500 µg/plate, or 
the equivalent of 50 µg/mL (Table 3) in the presence of S9, 
the homogenate from the rat liver. S9 contains the cytosol 
and microsomes and is used in AMES tests since some com-
pounds may only display a mutagenic activity upon activation 
via enzymes present in the homogenate. As a positive control, 
30 µg/plate of 2-anthramine or the equivalent of 1 µg/mL 
elicited a significant mutagenic activity with 20 times 
(mean 754±4 revertant colonies) the number of revertant 
colonies of E. coli, as the negative control.
Similarly, no mutagenic activity of Zolav® was observed 
at therapeutic concentrations in the absence of S9 (Table S1). 
The low cytotoxicity and lack of mutagenicity observed 
here are similar to those of other first-generation antibiotics 
belonging to this class.6,7,9
The in vivo effectiveness of Zolav® was tested in a 
P. acnes mouse intradermal model where the skin at the 
infection site was removed, homogenized, and subjected to 
CFU counts. At 2 hours postinfection, mice from the vehicle 
Table 1 Mic (µg/ml) of Zolav® and clindamycin (control) against 
P. acnes
Test strain Strain ID Zolav® Clindamycin
P. acnes aTcc 11827 2 0.063
P. acnes aTcc 29399 2 0.063
P. acnes aTcc 6919 2 0.063
Abbreviations: P. acnes, Propionibacterium acnes; Mic, minimum inhibitory 
concentration.
Table 2 cytotoxicity of Zolav® and staurosporin (control) in cell lines
Cell line Species GI50 TGI LC50
Zolav® hUVec human 30 µM 30 µM 30 µM
lung a549 human 30 µM 30 µM 30 µM
lung nci-h460 human 30 µM 30 µM 30 µM
staurosporin hUVec human 1.0 nM 11.0 nM 0.023 µM
lung a549 human 2.0 nM 0.052 µM 0.17 µM
lung nci-h460 human 8.0 nM 0.3 µM 0.61 µM
Abbreviations: gi50, growth inhibition in 50% concentration; Tgi, total growth inhibition; lc50, lethal concentration of 50%; hUVec, human umbilical vein endothelial cells.




new antibiotic treatment for acne
group were harvested showing a mean baseline bacterial 
burden of 5.78 log 10 (n=3). The remaining mice were 
harvested at 96 hours post-challenge. The skin CFU burden 
in mice in the negative control group has shown a mean 
bacterial burden of 7.17 log 10 at 96 hours (n=5) (Figure 1; 
Table S2). The group treated with the Zolav® showed a 
bacterial burden at 96 hours of 5.07 log 10 (P=0.0252) 
(n=5), a significant difference (2.10 log 10) to the negative 
control group and a 0.71 log reduction compared to the mean 
baseline bacterial burden. None of the mice in the study 
displayed any acute adverse events associated with the treat-
ments, and none of the mice succumbed to the infection or 
have shown signs of morbidity, which could be attributed 
to penetration of the infection into the circulatory system 
or deep tissue. Consistent with the significant decrease 
of P. acnes CFU burden in the group treated with Zolav® 
compared to the untreated group, photographs of mice 
from the two groups taken after 26 hours and after 50 hours 
demonstrate a reduction of inflammation, as indicated by 
the reduced redness, as well as a reduction in lesions in the 
treatment group (Figure S1). It is worth mentioning that no 
optimization of the treatment conditions, including doses, 
frequency of administration, and length of treatment, was 
attempted in this study. In future work, we will investigate 
the effect of shorter treatment times, lower doses, and twice 
a day administration or even once a day administration on 
the overall outcome of treatment, prior to toxicity assessment 
and first-in-man clinical trials.
Conclusion
In summary, we have established the in vitro and in vivo 
efficacy of Zolav® against P. acnes, and we have shown 
the low cytotoxic nature of the antibiotic and its lack of 
mutagenic activity. We show that a final concentration of 
50 µg/mL is effective in reducing the P. acnes burden in 
a mouse intradermal infection model. These results show 
the potential of Zolav® as a novel, affordable, effective, and 
low-risk treatment option for acne.
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Supplementary materials
Table S1 activity of Zolav® on revertant colonies of Escherichia coli in the absence of s9
Treatment Concentration S9 Revertant colonies/plate (n=3)
Escherichia coli (ATCC 49979)
Individual Mean ± SD
spontaneous revertant – (−) 32 33 28 31±3
DMsO (solvent) 100 µg/plate (−) 33 30 26 30±3
K2cr2O7 30 µg/plate (−) 146 147 142 145±3*
Zolav® 1,500 µg/plate (−) 25 29 29 28±3
150 µg/plate (−) 35 29 21 28±7
15 µg/plate (−) 23 32 30 28±4
1.5 µg/plate (−) 34 33 36 34±2
Notes: Significant mutagenic activity ($3× of control) denoted as (*). number of revertant colonies/plate is shown for each individual plate. s9 – homogenate from the rat 
liver containing the cytosol and microsomes. Mean ± sD value for triplicate plates of each treatment was calculated and shown after the individual plate counts.
Abbreviations: aTcc, american Type culture collection; DMsO, dimethyl sulfoxide; sD, standard deviation.
Table S2 summary of Propionibacterium acnes intradermal infection model in mice in cFU/g (log10)
Mouse Vehicle control – 2 hours  
(baseline)
Vehicle  
control – 96 hours
Zolav® 50 μg/mL 
(q8h) – 96 hours
1 4.56 5.51 4.46
2 4.60 5.46 4.87
3 6.23 6.54 5.00
4 6.78 4.88
5 7.81 5.50
Mean 5.78 7.17 5.07
sD 0.956 0.979 0.374
seM 0.552 0.438 0.167
Abbreviations: seM, standard error of the mean; sD, standard deviation; q8h, every 8 hours.
Figure S1 comparison of infection area between treated and untreated mice.
Notes: Pictures of mice from the untreated group (A and B) and Zolav® at 50 µg/ml q8h (C and D) treated group at 26 hours (A and C) and at 50 hours (B and D) after 
challenge.
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